

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/625,307
		Filing Date	July 23, 2003
		First Named Inventor	Julia Elizabeth Thompson
		Group Art Unit	1644
		Examiner Name	Phillip Gambel
Sheet 1 of 13	Attorney Docket Number	05569.0007.CPUS02	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
SC	A1	4,816,397	03-28-1989	Boss et al.	
	A2	4,946,778	08-07-1990	Ladner et al.	
	A3	5,223,409	06-29-1993	Ladner et al.	
	A4	5,772,998	06-30-1998	Dasch et al.	
	A5	5,783,185	07-21-1998	Dasch et al.	
	A6	6,090,383	07-18-2000	Dasch et al.	
	A7	5,395,750	03-07-1995	Dillon et al.	
	A8	6,248,516	06-19-2001	Winter et al.	
	A9	5,885,793	03-23-1999	Griffiths et al.	
	A10	6,331,415	12-18-2001	Cabilly et al.	
	A11	5,091,513	02-25-1992	Huston et al.	
	A12	5,262,319	11-06-1993	Iwata et al.	
	A13	5,571,714	11-05-1996	Dasch et al.	
	A14	5,585,089	12-17-1996	Queen et al.	
	A15	5,616,561	04-01-1997	Barcellos-Hoff	
	A16	5,662,904	09-02-1997	Ferguson et al.	
	A17	6,419,928	07-16-2002	Dasch et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
M	B1	WO 88/06630	09-07-1988	Genex Corp.		
	B2	WO 88/09344	12-01-1988	Creative Biomolecules, Inc.		
	B3	EP 0 324 162	12-24-1988	Pluckthun et al.		
	B4	AU-B-27617/88	07-06-1989	Pluckthun et al.		
	B5	WO 90/02809	03-22-1990	Protein Engineering Corp.		
	B6	WO 90/05144	05-17-1990	Medical Research Council		
	B7	WO 90/14424	11-29-1990	Scripps Clinic & Research		

Examiner Signature	PHILLIP GAMBEL 9/24/07	Date Considered	
--------------------	------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds codes of USPTO Patent Documents as [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	10/625,307
		<b>Filing Date</b>	July 23, 2003
		<b>First Named Inventor</b>	Julia Elizabeth Thompson
		<b>Group Art Unit</b>	1644
		<b>Examiner Name</b>	Phillip Gambel
		<b>Attorney Docket Number</b>	05569.0007.CPUS02
(use as many sheets as necessary)			
Sheet	2	13	

<i>PC</i>	B8	WO 90/14430	11-29-1990	Foundation		
	B9	WO 90/14443	11-29-1990	Scripps Clinic & Research Foundation		
	B10	WO 91/10737	07-25-1991	Huse		
	B11	WO 91/17271	11-14-1991	Molecular Affinities Corp.		
	B12	WO 92/06204	04-16-1992	Affymax Technologies, N.V.		
	B13	WO 92/09690	06-11-1992	Ixsys, Inc.		
	B14	WO 92/18619	10-29-1992	Genentech, Inc.		
	B15	EP 0 368 684	03-09-1994	Scripps Research Institute		
	B16	EP A 0120694	10-03-1984	Medical Research Council		
	B17	EP A 0125023	11-14-1984	Celltech Limited		
	B18	EP A 184187	06-11-1986	Genentech, Inc. et al.		
	B19	EP A 0239400	09-30-1987	Teijin Limited		
	B20	EP B 0239400	09-30-1987	Winter		
	B21	GB 2188638	10-07-1987	Winter		
	B22	WO 91/04748	04-18-1991	Winter		
	B23	WO 92/01047	01-23-1992	La Jolla Cancer Research Foundation		
	B24	WO 92/17206	10-15-1992	Cambridge Antibody Technology Ltd et al.		
	B25	WO 92/20791	11-26-1992	The Victoria University of Manchester		
	B26	WO 93/06213	04-01-1993	Cambridge Antibody Technology Ltd et al.		
	B27	WO 93/11161	06-10-1993	Medical Research Council et al.		
	B28	WO 93/11236	06-10-1993	Enzon, Inc.		
	B29	WO 93/14782	08-05-1993	Medical Research Council et al.		
	B30	WO 93/17708	09-16-1993	La Jolla Cancer Research Foundation		
	B31	WO 93/19783	10-14-1993	Reed		
	B32	WO 93/21945	11-11-1993	The Whittier Institute for Diabetes and Endocrinology		
	B33	WO 94/13804	06-11-1992	The Regents of the Univ. of Cal., et al.		
	B34	WO 94/18227	08-18-1994	Cambridge Antibody Technology Ltd. et al.		
				Denzyme APS		

<b>Examiner Signature</b>	<i>Phillip Gambel</i>	<b>Date Considered</b>	9/24/07
---------------------------	-----------------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		
		<b>Application Number</b>	10/625,307	
		<b>Filing Date</b>	July 23, 2003	
		<b>First Named Inventor</b>	Julia Elizabeth Thompson	
		<b>Group Art Unit</b>	1644	
		<b>Examiner Name</b>	Phillip Gambel	
<b>Sheet</b>	3	13	<b>Attorney Docket Number</b>	05569.0007.CPUS02

B35	WO 95/13827	05-26-1995	The University of Sydney		
B36	GB 2 288 118 A	10-11-1995	The Victoria University of Manchester		
B37	WO 97/13844	04-17-1997	Cambridge Antibody Technology, Ltd.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published		T <sup>2</sup>
	C1	Bouanani, M. et al., "Autoimmunity to Human Thyrolobulin," Arthritis and Rheumatism, 34(12):1585-1593 (1991)		
	C2	James, K. and Bell, G.T., "Human Monoclonal Antibody Production: Current Status and Future Prospects," Journal of Immunological Methods, 100:5-40 (1987)		
	C3	Kim, J.G. and Abeyounis, C.J., "Isolation and Characterization of Rat Carcinoembryonic Antigen," Int. Arch. Allergy Appl. Immunol., 92:43-49 (1990)		
	C4	Kim, J.G. and Abeyounis, C.J., "Monoclonal Rat Antibodies to Rat Carcinoembryonic Antigen," Immunological Investigations, 17(I):41-48 (1988)		
	C5	Portolano, S. et al., "A Human FAB Fragment Specific for Thyroid Peroxidase Generated by Cloning Thyroid Lymphocyte-Derived Immunoglobulin Genes in a Bacteriophage Lambda Library," Biochemical and Biophysical Research Communications, 179(I):372-377 (1991)		
	C6	Avrameas, "Natural Autoantibodies: From 'Horror Autotoxicus' to 'Gnothi Seauton'", Immunology Today 12:154-159 (1991)		
	C7	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties," Proteins, Structure, Function and Genetics 8:309-314 (1990)		
	C8	Bendtzen et al., "Autoantibodies to Cytokines – Friends or Foes?," Immunology Today 11(5):167-169 (1990)		

<b>Examiner Signature</b>	<i>Phillip Gambel 9/24/07</i>	<b>Date Considered</b>	
---------------------------	-------------------------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/625,307
		<b>Filing Date</b>	July 23, 2003
		<b>First Named Inventor</b>	Julia Elizabeth Thompson
		<b>Group Art Unit</b>	1644
		<b>Examiner Name</b>	Phillip Gambel
<b>Attorney Docket Number</b>	05569.0007.CPUS02		
Sheet	4	13	

26	C9	de la Cruz et al., "Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," J. Biol. Chem. 263(9):4318-4322 (1988)	
	C10	Ditzel et al., "The Nature of the Autoimmune Antibody Repertoire in Human Immunodeficiency Virus Type 1 Infection," Proc. Natl. Acad. Sci. USA 91:3710-3714 (1994)	
	C11	Hassan et al., "Prevalence of Anti-Fab Antibodies in Patients with Autoimmune and Infectious Diseases," Clin. exp. Immunol. 89:423-426 (1992)	
	C12	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," Science 246:1275-1281 (1989)	
	C13	Jerome et al., "Adenocarcinoma Reactive Cytotoxic T Lymphocytes Recognize an Epitope Present on the Protein Core of Epithelial Mucin Molecules," Cellular Immunity and the Immunotherapy of Cancer, pages 321-328 (1990)	
	C14	Kang et al., "Linkage of Recognition and Replication Functions by Assembling Combinatorial Antibody Fab Libraries Along Phage Surface," Proc. Natl. Acad. Sci. USA 88:4363-4366 (1991)	
	C15	Leusch et al., "Failure to Demonstrate TNF $\alpha$ -Specific Autoantibodies in Human Sera by ELISA and Western Blot," Journal of Immunological Methods 139:145-147 (1991)	
	C16	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," Bio/Technology 10:779-783 (1992)	
	C17	McCafferty et al., "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," Nature 348:552-554 (1990)	
	C18	Milstein, F.R.S., "Antibodies: a Paradigm for the Biology of Molecular Recognition," Proc. R. Soc. London B 239:1-16 (1990)	

<b>Examiner Signature</b>	<i>Phillip Gambel</i> 9/24/07	<b>Date Considered</b>	
---------------------------	-------------------------------	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			<b>Application Number</b>	10/625,307
			<b>Filing Date</b>	July 23, 2003
			<b>First Named Inventor</b>	Julia Elizabeth Thompson
			<b>Group Art Unit</b>	1644
			<b>Examiner Name</b>	Phillip Gambel
<b>Sheet</b>	5	13	<b>Attorney Docket Number</b>	05569.0007.CPUS02

pg 1	C19	Moynier et al., "The B Cell Repertoire in Rheumatoid Arthritis. I. Frequency of EBV-Inducible Circulating Precursors Producing Autoantibodies," Journal of Autoimmunity 4:631-649 (1991)	
	C20	Nossal, "Immunologic Tolerance: Collaboration Between Antigen and Lymphokines," Science 245:147-153 (1989)	
	C21	Parmley and Smith, "Antibody-Selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes," Gene 73:305-318 (1988)	
	C22	Sanz et al., "Nucleotide Sequences of Eight Human Natural Autoantibody V <sub>H</sub> Regions Reveals Apparent Restricted Use of V <sub>H</sub> Families," The Journal of Immunology 142(11):4051-4061 (1989)	
	C23	Sekigawa et al., "Characterization of Autoantibodies to the CD4 molecule in Human Immunodeficiency Virus Infection," Clinical Immunology and Immunopathology 58:145-153 (1991)	
	C24	Short et al., "λ ZAP: a Bacteriophage λ Expression Vector with In Vivo Excision Properties," Nucleic Acids Research 16(15):7583-7600 (1988)	
	C25	Smith, "Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion Surface," Science 228:1315-1317 (1985)	
	C26	Tsunetsugu-Yokota et al., "Expression of an Immunogenic Region of HIV by a Filamentous Bacteriophage Vector," Gene 99:261-265 (1991)	
	C27	Winter and Milstein, "Man-Made Antibodies," Nature 349:293-299 (1991)	
	C28	Yativ et al., "The Detection of Antithyroglobulin Activity in Human Serum Monoclonal Immunoglobulins (Monoclonal Gammopathies)," Immunol. Res. 12:330-337 (1993)	
	C29	International Search Report: PCT/GB92/02240	
pg 2	C30	Border et al., "Suppression of Experimental Glomerulonephritis by Antiserum Against Transforming Growth Factor β1," Nature, 346:371-374 (1990)	

<b>Examiner Signature</b>	<i>Phillip Gambel</i> 9/24/07	<b>Date Considered</b>	
---------------------------	-------------------------------	------------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>	10/625,307	
			<b>Filing Date</b>	July 23, 2003	
			<b>First Named Inventor</b>	Julia Elizabeth Thompson	
			<b>Group Art Unit</b>	1644	
			<b>Examiner Name</b>	Phillip Gambel	
<b>Attorney Docket Number</b>	05569.0007.CPUS02				
Sheet	6	13			

	C31	Dasch et al., "Monoclonal Antibodies Recognizing Transforming Growth Factor- $\beta$ : Bioactivity Neutralization and Transforming Growth Factor $\beta$ 2 Affinity Purification," J. Immunol., 142(5):1536-1541 (1989)	
	C32	Larrick et al., "Recombinant Antibodies," Hum. Antibody. Hybridomas, 2:172-189 (1991)	
	C33	Bagshawe et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites," Antibody, Immunoconjugates and Radiopharmaceuticals, 4:915-922 (1991)	
	C34	Barbas et al., "High-Affinity Self-Reactive Human Antibodies by Design and Selection: Targeting the Integrin Ligand Binding Site," Proc. Natl. Acad. Sci., USA, 90:10003-10007 (1993)	
	C35	Barbas et al., "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," Proc. Natl. Acad. Sci., USA, 91:3809-3813 (1994)	
	C36	Bebbington et al., "High-Level Expression of a Recombinant Antibody From Myeloma Cells Using a Glutamine Synthetase Gene As An Amplifiable Selectable Marker," Bio/Technology, 10:169-175 (1992)	
	C37	Bird R. et al., "Single-Chain Antigen-Binding Proteins," Science, 242:423-426 (1988)	
	C38	Brown et al., "Physiochemical Activation of Recombinant Latent Transforming Growth Factor-beta's 1, 2, and 3," Growth Factors, 3:35-43 (1990)	
	C39	Burmester et al., "Mutational Analysis of a Transforming Growth Factor- $\beta$ Receptor Binding Site," Growth Factors, 15:231-242 (1998)	
	C40	Bye et al., "Germline Variable of Gene Segment Derivation of Human Monoclonal Anti-Rh(D) Antibodies," J. Clin. Invest., 90(6):2481-2490	
	C41	Conner et al., "Correlation of Fibrosis and Transforming Growth Factor- $\beta$ type 2 Levels in the Eye," J. Clin. Invest., 83:1661-1666 (1989)	

<b>Examiner Signature</b>	<i>P. H. GAMBEL</i>	<b>Date</b>	9/24/07	<b>Considered</b>	
---------------------------	---------------------	-------------	---------	-------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>	10/625,307	
			<b>Filing Date</b>	July 23, 2003	
			<b>First Named Inventor</b>	Julia Elizabeth Thompson	
			<b>Group Art Unit</b>	1644	
			<b>Examiner Name</b>	Phillip Gambel	
<b>Sheet</b>	7	13	<b>Attorney Docket Number</b>		05569.0007.CPUS02

<i>pk</i>	C42	Danielpour et al., "Immunodetection and Quantitation of the Two Forms of Transforming Growth Factor-Beta (TGF- $\beta$ 1 and TGF- $\beta$ 2) Secreted by Cells in Culture," J. Cellular Physiology, 138:79-86 (1989)	
	C43	Danielpour et al., "Sandwich Enzyme-Linked Immunosorbent Assays (SELISAs) Quantitate and Distinguish Two Forms of Transforming Growth Factor -Beta (TGF- $\beta$ 1 and TGF- $\beta$ 2) in Complex Biological Fluids," Growth Factors, 2:61-71 (1989)	
	C44	Daopin et al., "Crystal Structure of TGF- $\beta$ 2 Refined at 1.8 A Resolution," Proteins: Structure, Function and Genetics, 17:176-192 (1993)	
	C45	Derynck et al., "The Murine Transforming Growth Factor- $\beta$ Precursor," J. Biol. Chem., 261:4377-4379 (1986)	
	C46	Erlenbacher et al., "Increased Expression of TGF- $\beta$ 2 in Osteoblasts Results in an Osteoporosis-like Phenotype," J. Cell Biology, 132:195-210 (1996)	
	C47	Fisch, I. et al., "A Strategy of Exon Shuffling for Making Large Peptide Repertoires Displayed on Filamentous Bacteriophage," Proc. Natl. Acad. Sci., USA, 93:7761-7766 (1996)	
	C48	Flanders et al., "Antibodies to Peptide Determinants in Transforming Growth Factor $\beta$ and Their Applications," Biochemistry, 27:739-746 (1988)	
	C49	Flanders et al., "Antibodies to Transforming Growth Factor- $\beta$ 2 Peptides: Specific Detection of TGF- $\beta$ 2 in Immunoassays," Growth Factors, 3:45-52 (1990)	
	C50	Flanders et al., "Localization and Actions of Transforming Growth Factor- $\beta$ s in the Embryonic Nervous System," Development, 113:183-191 (1991)	
	C51	Foreman et al., "A Simple Organ Culture Model for Assessing the Effects of Growth Factors on Corneal Re-epithelialization," Exp-Eye Res., 62:555-564 (1996)	
<i>pk</i>	C52	Gibson, Toby James, Studies in the Epstein-Barr Virus Genome, University of Cambridge: Ph.D. Dissertation, Date approved: 7 December 1984, BLDSC number: D58257/85, University of Cambridge, MRC Laboratory of Molecular Biology	

<b>Examiner Signature</b>	<i>PHILLIP GAMBEL</i>	<b>Date Considered</b>	9/24/07
---------------------------	-----------------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>	10/625,307
		<b>Filing Date</b>	July 23, 2003
		<b>First Named Inventor</b>	Julia Elizabeth Thompson
		<b>Group Art Unit</b>	1644
		<b>Examiner Name</b>	Phillip Gambel
<b>Attorney Docket Number</b>	05569.0007.CPUS02		
Sheet	8		13

<i>de</i>	C53	Giri et al., "Effect of Antibody to Transforming Growth Factor $\beta$ on Bleomycin Induced Accumulation of Lung Collagen in Mice," Thorax, 48:959-966 (1993)	
	C54	Gram et al., "In Vitro Selection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library," Proc. Natl. Acad. Sci., USA, 89 :3576-3580 (1992)	
	C55	Griffiths, A.D. et al., "Human Anti-Self Antibodies with High Specificity From Phage Display Libraries," EMBO J., 12(2) :725-734 (1993)	
	C56	Griffiths, A.D., et al., "Isolation of High Affinity Human Antibodies Directly from Large Synthetic Repertoires," EMBO J., 13(14) :3245-3260 (1994)	
	C57	Griffiths et al., "Three-Dimensional Structure of Recombinant Human Osteogenic Protein 1 : Structural Paradigm for the Transforming Growth Factor b Superfamily," Proc. Natl. Acad. Sci., USA, 93 :878-883 (1996)	
	C58	Hoefer et al., "Anti-(Transforming Growth Factor $\beta$ ) Antibodies with Predefined Specificity Inhibit Metastasis of Highly Tumorigenic Human Xenotransplants in nu/nu Mice," Cancer Immunol. Immunother., 41:302-308 (1995)	
	C59	Hollinger P. et al., "Engineering Bispecific Antibodies," Current Opinion in Biotechnology, 4:446-449 (1993)	
	C60	Hollinger P. et al., "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," Proc. Natl. Acad. Sci., USA, 90:6444-6448 (1993)	
	C61	Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-CH3) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Research, 56:3055-3061 (1996)	
<i>de</i>	C62	Huston J.S. et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in Escherichia coli," Proc. Natl. Acad. Sci., USA, 85:5879-5883 (1988)	

Examiner Signature	<i>Phillip Gambel</i>	Date Considered	9/14/02
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		
		Application Number	10/625,307	
		Filing Date	July 23, 2003	
		First Named Inventor	Julia Elizabeth Thompson	
		Group Art Unit	1644	
		Examiner Name	Phillip Gambel	
Sheet	9	13	Attorney Docket Number	05569.0007.CPUS02

P6	C63	Ikeda et al., "Human Transforming Growth Factor Type $\beta$ 2: Production by a Prostatic Adenocarcinoma Cell Line, Purification, and Initial Characterization," Biochemistry, 26:2406-2410 (1987)	
	C64	Jampel et al., "Transforming Growth Factor- $\beta$ in Human Aqueous Humor," Current Eye Research, 9:963-969 (1990)	
	C65	Karlsson et al., "Kinetic Analysis of Monoclonal Antibody-Antigen Interactions with a New Biosensor Based Analytical System," J. Immunological Methods, 145:229-240 (1991)	
	C66	Kaufman, R.J., "Selection and Coamplification of Heterologous Genes in Mammalian Cells," Methods Enzymology, 185:537-566 (1990)	
	C67	Khaw et al., "Activation and Suppression of Fibroblast Function," Eye, 8:188-195 (1994)	
	C68	Kvanta, A., "Expression and Secretion of Transforming Growth Factor- $\beta$ in Transformed and Nontransformed Retinal Pigment Epithelial Cells," Ophthalmic Res., 26:361-367 (1994)	
	C69	Ledermann et al., "A Phase-I Study of Repeated Therapy with Radiolabelled Antibody to Carcinoembryonic Antigen Using Intermittent or Continuous Administration of Cyclosporin A to Suppress the Immune Response," Int. J. Cancer, 47:659-664 (1991)	
	C70	Logan et al., "Effects of Transforming Growth Factor $\beta$ 1 on Scar Production in the Injured Central Nervous System of the Rat," European J. Neuroscience, 6:355-363 (1994)	
	C71	Logan et al., "Enhanced Expression of Transforming Growth Factor $\beta$ 1 in the Rat Brain After a Localized Cerebral Injury," Brain Research, 587:P216-225 (1992)	
	C72	Lucas et al., "Generation of Antibodies and Assays for Transforming Growth Factor $\beta$ ," Methods in Enzymology, 198:303-316 (1991)	
P5	C73	Lucas et al., "The Autocrine Production of Transforming Growth Factor- $\beta$ 1 During Lymphocyte Activation," J. Immunology, 145:1415-1422 (1990)	

Examiner Signature	<i>Phillip Gambel</i>	Date Considered	7/24/07
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		
		<b>Application Number</b>	10/625,307	
		<b>Filing Date</b>	July 23, 2003	
		<b>First Named Inventor</b>	Julia Elizabeth Thompson	
		<b>Group Art Unit</b>	1644	
		<b>Examiner Name</b>	Phillip Gambel	
<b>Sheet</b>	10	13	<b>Attorney Docket Number</b>	05569.0007.CPUS02

<i>MB</i>	C74	Marks J.D. et al., "By-Passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage," J. Molecular Biology, 222:581-597 (1991)	
	C75	Massague et al., "The Transforming Growth Factor- $\beta$ Family," Annual Rev. Cell Biol., 6:597-641 (1990)	
	C76	McCafferty et al., "Selection and Rapid Purification of Murine Antibody Fragments that Bind a Transition-State Analog by Phage Display," Appl. Biochem. Biotech., 47:157-173 (1994)	
	C77	Merwin et al., "Vascular Cells Respond Differentially to Transforming Growth Factors Beta <sub>1</sub> and Beta <sub>2</sub> In Vitro," American J. Pathology, 138:37-51 (1991)	
	C78	Munro S. et al., "An Hsp70-like Protein in the ER: Identity with the 78 kd Glucose-Regulated Protein and Immunoglobulin Heavy Chain Binding Protein," Cell, 46:291-300 (1986)	
	C79	Nissim et al., "Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents," EMBO J., 13:692-698 (1994)	
	C80	Orlandi, R. et al., "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction," Proc. Natl. Acad. Sci., USA, 86:3833-3837 (1989)	
	C81	Ottman et al., "Differential Proliferative Effects of Transforming Growth Factor- $\beta$ on Human Hematopoietic Progenitor Cells," J. Immunology, 140:2661-2665 (1988)	
	C82	Pena et al., "Effects of TGF- $\beta$ and TGF- $\beta$ Neutralizing Antibodies on Fibroblast-Induced Collagen Gel Contraction: Implications for Proliferative Vitreoretinopathy," Investigative Ophthalmology Visual Science, 35:2804-2808 (1994)	
<i>MB</i>	C83	Pfeffer et al., "Transforming Growth Factor Beta 2 is the Predominant Isoform in the Neural Retina, Retinal Epithelium-Choroid and Vitreous of the Monkey Eye," Exp. Eye Res., 59:323-333 (1994)	

<b>Examiner Signature</b>	<i>Phillip Gambel</i>	<b>Date</b>	9/24/07
		<b>Considered</b>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>		
		<b>Application Number</b>	10/625,307	
		<b>Filing Date</b>	July 23, 2003	
		<b>First Named Inventor</b>	Julia Elizabeth Thompson	
		<b>Group Art Unit</b>	1644	
		<b>Examiner Name</b>	Phillip Gambel	
<b>Sheet</b>	11	13	<b>Attorney Docket Number</b>	05569.0007.CPUS02

<i>PC</i>	C84	Pircher et al., "β-Transforming Growth Factor is Stored in Human Blood Platelets as a Latent High Molecular Weight Complex," Biochemical Biophysical Research Communications, 136(1):30-37 (1986)	
	C85	Pluckthun, A., "Antibody Engineering: Advances From the Use of Escherichia Coli Expression Systems," Bio/Technology, 9:545-551 (1991)	
	C86	Qian et al., "Binding Affinity of Transforming Growth Factor-β for Its Type II Receptor is Determined by the C-terminal Region of the Molecule," J. Biol. Chem., 271:30656-30662 (1996)	
	C87	Randall et al., "A Novel, Sensitive Bioassay for Transforming Growth Factor β," J. Immunological Methods, 164:61-67 (1993)	
	C88	Reff, M.E., "High-level Production of Recombinant Immunoglobulins in Mammalian Cells," Current Opinion in Biotechnology, 4:573-576 (1993)	
	C89	Reiter et al., "Engineering Antibody Fv Fragments for Cancer Detection and Therapy: Disulfide-Stabilized Fv Fragments," Nature Biotechnology, 14:1239-1245 (1996)	
	C90	Ridgeway et al., "'Knos-into-holes' Engineering of Antibody C <sub>H</sub> 3 Domain for Heavy Chain Heterodimerization," Protein Engineering, 9:616-621 (1996)	
	C91	Roberts et al., "Mesoderm Induction in Xenopus laevis Distinguishes Between the Various TGF-β Isoforms," Growth Factors, 3:277-286 (1990)	
	C92	Roberts et al., "The Transforming Growth Factor-βs" in Handbook of Experimental Pharmacology, Eds. M.B. Sporn et al., Springer Heideberg, pp. 419-472 (1990)	
	C93	Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-Chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," J. Mol. Biol., 263:551-567 (1996)	
<i>PC</i>	C94	Schlunegger et al., "An Unusual Feature Revealed by the Crystal Structure at 2.2A Resolution of Human Transforming Growth Factor-β2," Nature, 358:430-434 (1992)	

<b>Examiner Signature</b>	<i>Phillip Gambel 9/24/07</i>	<b>Date Considered</b>	
---------------------------	-------------------------------	------------------------	--

\*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>		
			<b>Application Number</b>	10/625,307	
			<b>Filing Date</b>	July 23, 2003	
			<b>First Named Inventor</b>	Julia Elizabeth Thompson	
			<b>Group Art Unit</b>	1644	
			<b>Examiner Name</b>	Phillip Gambel	
Sheet	12	13	<b>Attorney Docket Number</b>		05569.0007.CPUS02

<i>Ref</i>	C95	Shah et al., "Control of Scarring in Adult Wounds by Neutralizing Antibody to Transforming Growth Factor $\beta$ ," Lancet, 339:213-214 (1992)	
	C96	Shah et al., "Neutralizing Antibody to TGF- $\beta_{1,2}$ Reduces Cutaneous Scarring in Adult Rodents," J. Cell Science, 107:1137-1157 (1994)	
	C97	Shah M. et al., "Neutralization of TGF- $\beta_1$ and TGF- $\beta_2$ or Exogenous Addition of TGF- $\beta_3$ to Cutaneous Rat Wounds Reduces Scarring," J. Cell Science, 108:985-1002 (1995)	
	C98	Stemmer et al., "Rapid Evolution of a Protein In Vitro by DNA Shuffling," Nature, 370:389-391 (1994)	
	C99	Saurdet et al., "Responsiveness of Three Newly Established Human Colorectal Cancer Cell Lines to Transforming Growth Factors $\beta_1$ and $\beta_2$ ," Cancer Research, 52:3705-3712 (1992)	
	C100	Tahara et al., "Synthetic Peptide-Generated Monoclonal Antibodies to Transforming Growth Factor- $\beta_1$ ," Hybridoma, 12(4):441-453 (1993)	
	C101	Traunecker, A. et al., "Bispecific Single Chain Molecules (Janusins) Target Cytotoxic Lymphocytes on HIV Infected Cells," EMBO J., 10(12):3655-3659 (1991)	
	C102	Trill J.J. et al., "Production of Monoclonal Antibodies in COS and CHO Cells," Current Opinion in Biotechnology, 6:553-560 (1995)	
	C103	Wahl et al., "Reversal of Acute and Chronic Synovial Inflammation by Anti-Transforming Growth Factor $\beta$ ," J. Experimental Medicine, 177:225-230 (1993)	
	C104	Wakefield et al., "Recombinant TGF- $\beta_1$ is Synthesized as a Two-Component Latent Complex That Shares Some Structural Features with the Native Platelet Latent TGF- $\beta_1$ Complex," Growth Factors, 1:203-218 (1989)	
	C105	Ward, E.S. et al., "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia coli," Nature, 341:544-546 (1989)	
	C106	Winter, G. et al., "Man-Made Antibodies," Nature, 349:293-299 (1991)	

<b>Examiner Signature</b>	<i>Phillip Gambel</i>	<b>Date Considered</b>	9/24/03
---------------------------	-----------------------	------------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/625,307
<b>Filing Date</b>	July 23, 2003
<b>First Named Inventor</b>	Julia Elizabeth Thompson
<b>Group Art Unit</b>	1644
<b>Examiner Name</b>	Phillip Gambel
<b>Attorney Docket Number</b>	05569.0007.CPUS02

Sheet	13	13
-------	----	----

[illegible]

Examiner Signature	P. Hays / m30 9/24/07	Date Considered	
-----------------------	-----------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place mark here if English language Translation is attached.

Burden House Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.